Ambulatory capacity and disease progression as measured by the 6-minute-walk-distance in Duchenne muscular dystrophy subjects on daily corticosteroids

Neuromuscular Disorders

Volumn 23, Issue 8, 2013, Pages 618-623

  Goemans, Nathalie ^a   van den Hauwe, Marleen ^a   Wilson, Rosamund ^c   van Impe, Annelies ^a   Klingels, Katrijn ^b   Buyse, Gunnar ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c Granary House   (United Kingdom)

Author keywords

6 Min walk test; Ambulatory capacity; Corticosteroids; Disease evolution; Duchenne muscular dystrophy; Variability

Indexed keywords

DEFLAZACORT; PREDNISONE;

ADOLESCENT; AGE DISTRIBUTION; AMBULATORY MONITORING; ARTICLE; CHILD; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DUCHENNE MUSCULAR DYSTROPHY; FOLLOW UP; FUNCTION TEST; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PHYSICAL CAPACITY; PREDICTIVE VALUE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SIX MINUTE WALK DISTANCE; TREATMENT DURATION;

6-MIN WALK TEST; AMBULATORY CAPACITY; CORTICOSTEROIDS; DISEASE EVOLUTION; DUCHENNE MUSCULAR DYSTROPHY; VARIABILITY;

ADOLESCENT; ADRENAL CORTEX HORMONES; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; EXERCISE TEST; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MUSCULAR DYSTROPHY, DUCHENNE; OUTCOME ASSESSMENT (HEALTH CARE); RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84880950715     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2013.05.006     Document Type: Article

References (14)

1. Bushby K., Connor E. Clinical outcome measures for trials in Duchenne muscular dystrophy: report from international working group meetings. Clin Invest (London) 2011, 1(9):1217-1235.
2. Moxley R.T., Pandya S., Ciafaloni E., Fox D.J., Campbell K. Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management. J Child Neurol 2010, 25(9):1116-1129.
3. Manzur A.Y., Kuntzer T., Pike M., Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev 2008, 1:CD003725.
4. Biggar W.D., Harris V.A., Eliasoph L., Alman B. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord 2006, 16(4):249-255.
5. Dec G.W. Steroid therapy effectively delays Duchenne's cardiomyopathy. J Am Coll Cardiol 2013, 61(9):955-956.
6. Bushby K., Finkel R., Birnkrant D.J., et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 2010, 9(2):177-189.
7. Clarke L.A., Wraith J.E., Beck M., et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics 2009, 123(1):229-240.
8. McDonald C.M., Henricson E.K., Han J.J., et al. The 6-min walk test as a new outcome measure in Duchenne muscular dystrophy. Muscle Nerve 2010, 41(4):500-510.
9. McDonald C.M., Henricson E.K., Han J.J., et al. The 6-min walk test in Duchenne/Becker muscular dystrophy: longitudinal observations. Muscle Nerve 2010, 42(6):966-974.
10. Mazzone E., Vasco G., Sormani M.P., et al. Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study. Neurology 2011, 77(3):250-256.
11. Mazzone E.S., Pane M., Sormani M.P., et al. 24month longitudinal data in ambulant boys with duchenne muscular dystrophy. PLoS One 2013, 8(1):e52512.
12. Geiger R., Strasak A., Treml B., et al. Six-min walk test in children and adolescents. J Pediatr 2007, 150(4):395-399. 399 e1-2.
13. Henricson E., Abresch R., Han J.J., et al. Percent-predicted 6-min walk distance in duchenne muscular dystrophy to account for maturational influences. PLoS Curr 2012, 4:RRN1297.
14. Flanigan KM, Ceco E, Lamar KM, et al. LTBP4 genotype predicts age of ambulatory loss in Duchenne Muscular Dystrophy. Ann Neurol 2012. [Epub ahead of print]. http://dx.doi.org/10.1002/ana.23819.